ATE544457T1 - Verfahren zur behandlung bzw. prävention systemischer entzündungen - Google Patents

Verfahren zur behandlung bzw. prävention systemischer entzündungen

Info

Publication number
ATE544457T1
ATE544457T1 AT08730501T AT08730501T ATE544457T1 AT E544457 T1 ATE544457 T1 AT E544457T1 AT 08730501 T AT08730501 T AT 08730501T AT 08730501 T AT08730501 T AT 08730501T AT E544457 T1 ATE544457 T1 AT E544457T1
Authority
AT
Austria
Prior art keywords
prevention
procedure
treatment
systemic inflammation
infant
Prior art date
Application number
AT08730501T
Other languages
English (en)
Inventor
Robert Mcmahon
William Michael Russell
Udo Herz
Josef Neu
Original Assignee
Mead Johnson Nutrition Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39469924&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE544457(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Mead Johnson Nutrition Co filed Critical Mead Johnson Nutrition Co
Application granted granted Critical
Publication of ATE544457T1 publication Critical patent/ATE544457T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/745—Bifidobacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT08730501T 2007-02-28 2008-02-22 Verfahren zur behandlung bzw. prävention systemischer entzündungen ATE544457T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US90412207P 2007-02-28 2007-02-28
PCT/US2008/054710 WO2008106372A1 (en) 2007-02-28 2008-02-22 Method for treating or preventing systemic inflammation

Publications (1)

Publication Number Publication Date
ATE544457T1 true ATE544457T1 (de) 2012-02-15

Family

ID=39469924

Family Applications (1)

Application Number Title Priority Date Filing Date
AT08730501T ATE544457T1 (de) 2007-02-28 2008-02-22 Verfahren zur behandlung bzw. prävention systemischer entzündungen

Country Status (13)

Country Link
US (2) US9408818B2 (de)
EP (2) EP2124977B9 (de)
CN (3) CN105796607A (de)
AT (1) ATE544457T1 (de)
BR (2) BRPI0808052A2 (de)
CA (2) CA2679374C (de)
ES (2) ES2381232T3 (de)
MX (2) MX2009009119A (de)
MY (2) MY145769A (de)
PL (2) PL2114423T3 (de)
RU (2) RU2468807C2 (de)
TW (2) TWI418355B (de)
WO (2) WO2008106372A1 (de)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7767203B2 (en) 1998-08-07 2010-08-03 Ganeden Biotech, Inc. Methods for the dietary management of irritable bowel syndrome and carbohydrate malabsorption
US9408818B2 (en) * 2007-02-28 2016-08-09 Mead Johnson Nutrition Company Method for the utilization of and product containing inactivated probiotic
EP2227239A2 (de) * 2007-12-06 2010-09-15 Arla Foods Amba Probiotische bakterien und regulierung der fettspeicherung
US9034314B2 (en) * 2008-11-03 2015-05-19 Nestec S.A. Nutritional composition comprising probiotics and improving sleep patterns
EP2424550B1 (de) * 2009-04-29 2017-06-07 Ganeden Biotech, Inc. Bakterienzellmembran formulierung
US8784798B2 (en) * 2009-05-11 2014-07-22 Nestec S.A. Bifidobacterium longum NCC2705 (CNCM I-2618) and immune disorders
EP2251020A1 (de) * 2009-05-11 2010-11-17 Nestec S.A. Kurzzeitige Hochtemperaturbehandlung erzeugt mikrobielle Zubereitungen mit entzündungshemmenden Profilen
EP2251022A1 (de) * 2009-05-11 2010-11-17 Nestec S.A. Nicht-replizierte Mikroorganismen und deren immunstärkender Effekt
CA2786710C (en) 2010-01-19 2018-10-09 Abbott Laboratories Nutritional formulas containing synbiotics
US9301982B2 (en) 2010-04-14 2016-04-05 Ganeden Biotech, Inc. Probiotic confection and lipid compositions
EP2455092A1 (de) * 2010-11-11 2012-05-23 Nestec S.A. Nicht replizierende probiotische Mikroorganismen als Schutz vor Infektionen der oberen Atemwege
BR112013010783A2 (pt) * 2010-11-11 2016-07-12 Nestec Sa confecções congeladas contendo micro-organismos probióticos
EP2452576A1 (de) * 2010-11-11 2012-05-16 Nestec S.A. Extrudierte nicht-replizierende probiotische Mikroorganismen und ihre positiven Auswirkungen auf die Gesundheit
EP2455093A1 (de) * 2010-11-11 2012-05-23 Nestec S.A. Nicht replizierende probiotische Bakterien und Prävention bzw. Behandlung von Infektionen bei Kindern
EP2455094A1 (de) * 2010-11-11 2012-05-23 Nestec S.A. Nicht replizierende probiotische Mikroorganismen als Schutz vor Magen-Darm-Infektionen bei Kindern
US11235008B2 (en) 2011-03-31 2022-02-01 Ganeden Biotech, Inc. Probiotic sports nutrition compositions
GB201112091D0 (en) 2011-07-14 2011-08-31 Gt Biolog Ltd Bacterial strains isolated from pigs
GB201117313D0 (en) 2011-10-07 2011-11-16 Gt Biolog Ltd Bacterium for use in medicine
KR101166798B1 (ko) 2011-12-19 2012-07-26 김대현 락토바실러스 애시도필러스 엘비의 사균을 포함하는 알레르기 질환의 치료 또는 예방용 의약 조성물
WO2013103826A1 (en) * 2012-01-06 2013-07-11 Skyview Enterprise Ltd. Anti-inflammatory compounds in combination with hydrogen for the treatment of inflammation
US20130251829A1 (en) * 2012-03-23 2013-09-26 Mead Johnson Nutrition Company Probiotic derived non-viable material for infection prevention and treatment
GB201306536D0 (en) 2013-04-10 2013-05-22 Gt Biolog Ltd Polypeptide and immune modulation
BR112016002650A2 (pt) * 2013-08-09 2017-09-12 Ab Biotics Sa probiótico para choro excessivo infantil
AU2014359705A1 (en) * 2013-11-25 2016-05-05 Nestec S.A. Heat-treated formulation of Bifidobacterium lactis NCC 2818 reduces allergic manifestations
CN106231924A (zh) * 2013-11-29 2016-12-14 雀巢产品技术援助有限公司 按年龄定制的具有不同蛋白质含量的营养组合物
PE20171138A1 (es) 2014-12-23 2017-08-09 4D Pharma Res Ltd Modulacion inmunitaria
DK3193901T3 (en) 2014-12-23 2018-05-28 4D Pharma Res Ltd PIRIN POLYPEPTIDE AND IMMUNMODULATION
MA41060B1 (fr) 2015-06-15 2019-11-29 4D Pharma Res Ltd Compositions comprenant des souches bactériennes
MA41010B1 (fr) 2015-06-15 2020-01-31 4D Pharma Res Ltd Compositions comprenant des souches bactériennes
LT3360559T (lt) 2015-06-15 2019-12-27 4D Pharma Research Limited Kompozicijos, apimančios bakterijų kamienus
PE20180243A1 (es) 2015-06-15 2018-01-31 4D Pharma Res Ltd Composiciones que comprenden cepas bacterianas
EP3662917A1 (de) 2015-06-15 2020-06-10 4D Pharma Research Limited Zusammensetzungen mit bakterienstämmen
MA41013A (fr) 2015-11-20 2017-08-30 4D Pharma Res Ltd Compositions comprenant des souches bactériennes
GB201520497D0 (en) 2015-11-20 2016-01-06 4D Pharma Res Ltd Compositions comprising bacterial strains
GB201520638D0 (en) 2015-11-23 2016-01-06 4D Pharma Res Ltd Compositions comprising bacterial strains
GB201520631D0 (en) 2015-11-23 2016-01-06 4D Pharma Res Ltd Compositions comprising bacterial strains
GB201612191D0 (en) 2016-07-13 2016-08-24 4D Pharma Plc Compositions comprising bacterial strains
MX373290B (es) 2016-03-04 2020-06-18 4D Pharma Plc Composiciones que comprenden cepas bacterianas.
TWI802545B (zh) 2016-07-13 2023-05-21 英商４Ｄ製藥有限公司 包含細菌菌株之組合物
ES2657665B1 (es) * 2016-09-05 2018-12-17 Pedro Jose DE LA FUENTE BLASCO Productos para la salud con probióticos inactivados y uso de dichos productos
GB201621123D0 (en) 2016-12-12 2017-01-25 4D Pharma Plc Compositions comprising bacterial strains
CN107115362A (zh) * 2017-04-28 2017-09-01 青岛东海药业有限公司 凝结芽孢杆菌在制备预防或治疗支气管哮喘制剂中的应用
MA48940A (fr) 2017-05-22 2020-04-08 4D Pharma Res Ltd Compositions comprenant des souches bactériennes
MA41708A (fr) 2017-05-24 2020-04-08 4D Pharma Res Ltd Compositions comprenant des souches bactériennes
JP2020523326A (ja) 2017-06-14 2020-08-06 フォーディー ファーマ リサーチ リミテッド４Ｄ Ｐｈａｒｍａ Ｒｅｓｅａｒｃｈ Ｌｉｍｉｔｅｄ 細菌株を含む組成物
TWI767013B (zh) 2017-06-14 2022-06-11 英商4D製藥研究有限公司 包含細菌品系之組成物
PL3638271T3 (pl) 2017-06-14 2021-03-22 4D Pharma Research Limited Kompozycje zawierające szczepy bakteryjne
CN108041607A (zh) * 2017-12-26 2018-05-18 广州普正生物科技有限公司 一种护齿益生菌咀嚼软胶囊
RU2770463C1 (ru) * 2020-10-14 2022-04-18 федеральное государственное бюджетное образовательное учреждение высшего образования "Алтайский государственный технический университет им. И.И. Ползунова" (АлтГТУ) Способ производства мягкого сыра
TWI802009B (zh) * 2021-09-16 2023-05-11 創百股份有限公司 使用熱致死的乳酸菌菌株來治療和/或預防微粒物質-誘發的肺損傷
WO2024236053A1 (en) 2023-05-15 2024-11-21 Bactopharma Gmbh Treatment of cancer therapy-induced oral mucositis
KR20260088528A (ko) 2023-10-09 2026-06-12 사이언스 파워 에스알엘 포스트바이오틱스 조성물의 제조 방법

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5804179A (en) 1985-12-31 1998-09-08 Research Corporation Technologies, Inc. Lactobacillus compositions and methods for treating urinary tract infections
US6156320A (en) * 1993-02-05 2000-12-05 Harry Parsekian Fermented milk nutraceuticals
RU2031586C1 (ru) * 1993-02-05 1995-03-27 Тамара Георгиевна Извекова Биологически активный кисломолочный продукт "ацидолакт-наринэ" и способ его получения
US6180100B1 (en) 1994-09-30 2001-01-30 Urex Biotech., Inc. Lactobacillus compositions and methods for treating urinary tract infections
FI104465B (fi) * 1995-06-14 2000-02-15 Valio Oy Proteiinihydrolysaatteja allergioiden hoitamiseksi tai estämiseksi, niiden valmistus ja käyttö
EP0965643B1 (de) 1998-06-17 2003-11-05 Societe Des Produits Nestle S.A. Mobile genetische Elemente als Werkzeuge zur genetischen Modifikation von L. delbrueckii oder L. helveticus
US6399055B1 (en) 1998-10-27 2002-06-04 Compagnie Gervais Danone Method and composition for treatment of infant diarrhea
CA2354054C (en) 1998-12-11 2011-04-12 Urex Biotech, Inc. Oral administration of lactobacillus for the treatment and prevention of urogenital infection
ID29150A (id) 1999-01-15 2001-08-02 Entpr Ireland Cs Penggunaan lactobacillus salivarius
US6613549B2 (en) 2000-02-10 2003-09-02 Urex Biotech, Inc. Probiotic therapy for newborns
IL156490A0 (en) 2000-12-18 2004-01-04 Probiohealth Probiotic compounds derived from lactobacillus casei strain ke01
KR100419132B1 (ko) 2000-12-29 2004-02-18 조성근 위·장 점막 부착성과 증식성, 내산성, 내담즙성 및헬리코박터 파일로리, 대장균 0157:ｈ7에 대한 항균성이우수한 락토바실러스 파라카제이 서브스패시즈 파라카제이ｃｓｋ 01
FI109602B (fi) * 2001-01-25 2002-09-13 Valio Oy Probioottiyhdistelmä
KR100845456B1 (ko) 2001-02-06 2008-07-10 소시에떼 데 프로듀이 네슬레 소시에떼아노님 젖산균 및 비피도균에 의한 내독소 결합
PE20030283A1 (es) 2001-07-26 2003-05-01 Alimentary Health Ltd Cepas de lactobacillus casei
US20030092163A1 (en) 2001-07-26 2003-05-15 Collins John Kevin Probiotic bifidobacterium strains
PE20030274A1 (es) 2001-07-26 2003-05-08 Alimentary Health Ltd Cepas de lactobacillus salivarius
EP1364586A1 (de) 2002-05-24 2003-11-26 Nestec S.A. Probiotika und Oraltoleranz
US20050100531A1 (en) 2002-06-13 2005-05-12 John Bienenstock Probiotic therapies
SI1565547T2 (sl) 2002-06-28 2013-02-28 Biosearch S.A. Probiotiäśni sevi, postopek za izbiranje le-teh, njihovi sestavki in njihova uporaba
US20040208863A1 (en) 2003-01-30 2004-10-21 James Versalovic Anti-inflammatory activity from lactic acid bacteria
US20050180962A1 (en) 2003-01-30 2005-08-18 Eyal Raz Inactivated probiotic bacteria and methods of use thereof
WO2004087178A1 (en) 2003-03-31 2004-10-14 Alimentary Health Limited A formulation comprising a bacterial strain
CA2532472C (en) 2003-06-23 2012-04-17 Nestec S.A. Infant or follow-on formula
WO2005085287A1 (en) 2004-03-03 2005-09-15 En-N-Tech, Inc. Treatments for contaminant reduction in lactoferrin preparations and lactoferrin-containing compositions
US20080255252A1 (en) * 2004-03-15 2008-10-16 Tissugen Pty. Ltd. Infectious Aetiology of Prostatic Disease and Methods to Identify Causative Agents
EP2308566B1 (de) 2005-04-08 2017-07-05 The Procter and Gamble Company Verwendung oral verabreichter probiotischer Bifidobakterien zum Nutzen der menschlichen Schönheit
AU2006233918B2 (en) * 2005-04-13 2012-06-21 Nestec S.A. Infant formula with probiotics
US20060233762A1 (en) * 2005-04-15 2006-10-19 Mcmahon Robert J Method for treating or preventing systemic inflammation in formula-fed infants
US20060233752A1 (en) * 2005-04-15 2006-10-19 Mcmahon Robert J Method for treating or preventing systemic inflammation in formula-fed infants
WO2006124630A2 (en) 2005-05-13 2006-11-23 New England Medical Center Hospitals, Inc. Compositions and methods for enhancing the efficacy of vaccines
US9408818B2 (en) * 2007-02-28 2016-08-09 Mead Johnson Nutrition Company Method for the utilization of and product containing inactivated probiotic

Also Published As

Publication number Publication date
RU2009135873A (ru) 2011-04-10
EP2124977A1 (de) 2009-12-02
MY151892A (en) 2014-07-14
RU2468808C2 (ru) 2012-12-10
TW200900075A (en) 2009-01-01
US20080206212A1 (en) 2008-08-28
MX2009008875A (es) 2009-08-28
CA2676956C (en) 2017-06-13
CN101636172A (zh) 2010-01-27
US9408818B2 (en) 2016-08-09
EP2124977B9 (de) 2012-05-02
EP2114423B1 (de) 2012-06-06
CN105796607A (zh) 2016-07-27
EP2124977B1 (de) 2012-02-08
RU2009135871A (ru) 2011-04-10
US20080206213A1 (en) 2008-08-28
HK1141729A1 (zh) 2010-11-19
TW200906426A (en) 2009-02-16
RU2468807C2 (ru) 2012-12-10
ES2381232T3 (es) 2012-05-24
BRPI0808052A2 (pt) 2014-06-24
CN101678053B (zh) 2015-12-16
CA2679374A1 (en) 2008-09-04
MY145769A (en) 2012-04-13
MX2009009119A (es) 2009-09-04
CA2679374C (en) 2016-05-31
HK1136969A1 (en) 2010-07-16
WO2008106373A1 (en) 2008-09-04
TWI494114B (zh) 2015-08-01
PL2124977T3 (pl) 2012-07-31
CA2676956A1 (en) 2008-09-04
EP2114423A1 (de) 2009-11-11
PL2114423T3 (pl) 2012-10-31
ES2388198T5 (es) 2020-07-14
WO2008106372A1 (en) 2008-09-04
BRPI0808145A2 (pt) 2021-03-23
TWI418355B (zh) 2013-12-11
ES2388198T3 (es) 2012-10-10
CN101678053A (zh) 2010-03-24
EP2114423B2 (de) 2020-01-01
US9408819B2 (en) 2016-08-09

Similar Documents

Publication Publication Date Title
BRPI0808052A2 (pt) Método para tratar ou prevenir inflamação sistêmica.
PH12014501749A1 (en) A nutritional composition comprising probiotics and improving sleep patterns
TW200612971A (en) Method for preventing or treating respiratory infections and acute otitis media in infants
MX2011012063A (es) Formula alimenticia para bebes y niños pequeños que comprenden probioticos para bebes y niños pequeños.
PH12019550208A1 (en) Hmos blends for use in infants or young children for health purposes
MX2009009931A (es) Probioticos para reducir el desarrollo de alergia en lactantes nacidos por cesarea.
DE502007002101D1 (de) Arzneimittel mit Dobesilat-Calcium zur Behandlung und Prophylaxe von Sehnenerkrankungen
MY169326A (en) Human milk oligosaccharides for preventing injury and/or promoting healing of the gastrointestinal tract
MY197622A (en) Methods for decreasing the incidence of necrotizing enterocolitis in infants, toddlers, or children using human milk oligosaccharides
MX2010005132A (es) Uso de oligosacaridos conteniendo n-acetilactosamina para maduración de las respuestas inmunes en neonatos.
PH12014500185A1 (en) Galactooligosaccharides for preventing injury and/or promoting healing of the gastrointestinal tract
ZA202004246B (en) Compositions comprising at least on n-acetylated and at least one fucosylated oligosaccharide for use in the promotion of digestive capacity in infants and young children
IL189104A (en) Pharmaceutical preparation containing lasalazide or sodium balasalazide for use in the treatment of gastrointestinal disorders.
PT1878738E (pt) 1-questose para tratar a alergia e a dermatite atópica
DK2190304T3 (da) Ernæringsformulering med højt energiindhold
EP4477262A3 (de) Nährstoffzusammensetzungen für säuglinge und/oder kleinkinder
TW200635574A (en) Use of a therapeutically effective amount of DHA and ARA in the manufacture of a medicament for the prevention or treatment of respiratory infections in infants
PH12017500466A1 (en) Nutritional compositions comprising sn-1(3) monoacylglycerols for use in the treatment of growth delay in infants or children
UA111872U (uk) Спосіб лікування еруптивного гінгівіту у дітей
DOP2005000170A (es) Metodo de prevencion o tratamiento de infeciones respiratorias en infantes
UA52520U (ru) Способ лечения нарушений функционального состояния кишечника у новорожденных и детей младенческого возраста
TWD144412S1 (zh) 固齒器
Watanabe et al. The effects of benzodiazepines on event-related potential indices of automatic and controlled processing in schizophrenia
UA6404U (en) Method for stimulating mental abilities in children
RU2006122217A (ru) Способ предупреждения острых респираторных вирусных инфекций у детей дошкольного возраста